메뉴 건너뛰기
.. 내서재 .. 알림
소속 기관/학교 인증
인증하면 논문, 학술자료 등을  무료로 열람할 수 있어요.
한국대학교, 누리자동차, 시립도서관 등 나의 기관을 확인해보세요
(국내 대학 90% 이상 구독 중)
로그인 회원가입 고객센터 ENG
주제분류

추천
검색

이용수

표지
📌
연구주제
📖
연구배경
🔬
연구방법
🏆
연구결과
AI에게 요청하기
추천
검색

초록· 키워드

오류제보하기
Purpose: Hepatocellular carcinomas are one of themost common malignancies in the world. However, noeffective therapeutic modality has been proven to prolongthe survival of patients in an inoperable stage. The purposeof this study was to determine the response rateand the toxicities of a combination of pirarubicin, UFT andleucovorin in patients with non-embolizable hepatocellularcarcinomas, or who had progressed during theirtranscatheter arterial chemoembolization treatment. Materials and Methods: Of 23 patients with a hepatocellularcarcinoma, 11 had progressed during a transcatheterarterial chemoembolization, with the other 12being transcatheter arterial chemoembolization-naive. Allthe patients were treated with pirarubicin (70 mg/m2 i.v.,day 1), UFT (350 mg/m2 P.O., day 1~21), and leucovorin(25 mg/m2 P.O., day 1~21). Results: Twenty patients were able to be evaluated,with a partial response being achieved in four, giving anoverall response rate of 20% (95% confidence interval,7~44%). The median overall survival time was 6 months,and the median survival time of the transcatheter arterialchemoembolization-naive patients was significantly longerthan that of those treated by transcatheter arterial chemoembolization(p=0.012). The most significant dose-limitingtoxicity was leucopenia and thrombocytopenia. Conclusion: The combination of pirarubicin, UFT andleucovorin therapies showed marginal antitumor activityand significant toxicity in patients with non-embolizableor failed transcatheter arterial chemoembolization hepatocellularcarcinomas. (Cancer Res Treat. 2002;34:280-283)

목차

등록된 정보가 없습니다.

참고문헌 (0)

참고문헌 신청

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!

이 논문의 저자 정보

최근 본 자료

전체보기

댓글(0)

0